Market focus on Biogen reflects ongoing developments in neurological therapy pipelines. Portfolio adjustments and coverage updates continue to shape visibility of the biotechnology company. The ...

As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape ...

MSPs have rejected the chance to make Scotland the first part of the UK to legalise assisted dying. The proposals, tabled by ...

The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026--2036), mainly attributed to the increasing prevalence of NMOSD, ...

The historic ruling by the Supreme Court of India could nudge the right to die with dignity debate in India forward ...

VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery sys ...

In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

A two-drug combination frequently used in anti-aging research causes brain damage in mice, report University of Connecticut researchers in the Proceedings of the National Academy of Sciences. The ...

Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin. This finding could potentially open ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings ...

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in ...